FDA Issues Alert on Counterfeit Botox: What Dermatology Clinicians Need to Know
The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.
New AAD Atopic Dermatitis Guidelines and Dupilumab Label Updates
Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.
Allergan Aesthetics Launches 2 Products For Acne-Prone Skin
Mona Gohara, MD, explained the importance of the products' impact on the skin barrier.
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.
Managing Mental Health Comorbidities in Adult Patients With Atopic Dermatitis
Researchers address the persisting gaps in managing mental health comorbidities within the framework of existing clinical practice guidelines.
FDA Accepts Supplemental Biologics License Applications for Bimekizumab to Treat HS
The submission stems from promising results from the phase 3 BE HEARD I and BE HEARD II trials.
Dupilumab Shows Superiority in Reducing Upper Respiratory Infections in Patients With AD
The risk of upper respiratory infection-related mortality was notably diminished in the study's dupilumab cohort.
New Data on Retinol: Patricia Farris, MD, Shares Insights on Anti-Aging
In this study, topical 0.1% retinol significantly improved crow’s feet, facial wrinkles, uneven skin tone, brown spots, and overall photoaging.
Pelthos Therapeutics Launches to Accelerate Commercialization of Treatment for Molluscum Contagiosum
The new launch is set to bring berdazimer topical gel, 10.3% to adults and pediatric patients over the age of 1 with molluscum contagiosum faster.
J-Code for Ycanth Officially Launches Today
The permanent J-code for the molluscum contagiosum treatment is now live.
COVID-19 Impacts on Hair Loss, Pemphigus, Urticaria, and Rare Diseases
Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.
AARS Responds to Valisure’s Data on Benzene in BPO Products
The statement said the petition came as a surprise to many ahead of AAD, and delves into the data complexity and patient considerations.
Connecting COVID-19 Research to Impact on Patients With Atopic Dermatitis
Two recent studies delve into outcomes of pediatric populations with atopic conditions and an overview of patient outcomes utilizing a Mendelian randomization analysis.
Frontline Forum Part 3: Challenges and Opportunities to Enhance Psoriasis Management
A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.
Frontline Forum Part 2: Challenges and Opportunities to Enhance Psoriasis Management
A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.
Frontline Forum Part 1: Challenges and Opportunities to Enhance Psoriasis Management
A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.
2024 AAD Annual Meeting Recap: Day 5
Catch up on coverage from the fifth and final day of the 2024 American Academy of Dermatology Annual Meeting.
Catching Up With Karan Lal, DO, MS FAAD
In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.
Environmental Factors Affecting Pigmentation And The Skin Exposome
Arianne Shadi Kourosh, MD, MPH, FAAD, shared pearls on environmental factors that can impact skin aging and pigmentation including visible light, IR radiation, location, and pollution.
Serving Those Who Serve Our Communities: Melanoma in Veterans and Firefighters
Rebecca Hartman, MD, MPH, FAAD, and Christine Kannler, MD, FAAD, took a deep dive into considerations and pearls to treat patients who have been exposed to extreme heat and chemicals in the line of duty.
2024 AAD Annual Meeting Recap: Day 4
Catch up on coverage from the fourth day of the 2024 American Academy of Dermatology Annual Meeting.
American Academy of Dermatology Upholds Diversity Policies in Face of Anti-DEI Proposal
A vote during the annual meeting will keep DEI initiatives in place and members are awaiting news on what those initiatives will look like.
Science Behind OTC Products to Enhance Care for Atopic Dermatitis, Acne, and Sun Protection
Menes Kizoulis shared key highlights from the research conducted alongside leading dermatologists, like Alan Irvine, MD, DSc, and Patricia Farris, MD, MS.
Late-Breaking Phase 2b Data Showed Efficacy of Injectable Polidocanol for Submental Fat Reduction
The injectable polidocanol exhibited high efficacy, quicker onset of benefit, reduced downtime, and fewer side effects lasting longer than 30 days.
Navigating Delusional Infestations in Dermatology
Jenny Murase, MD, said the average dermatologist manages 2-3 patients with delusional infestations every 5 years. Learn what to expect and how to manage it with empathy.
2024 AAD Annual Meeting Recap: Day 3
Catch up on coverage from the third day of the 2024 American Academy of Dermatology Annual Meeting.
Navigating Finances in Dermatology: Top 5 Considerations for Dermatologists
In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.
Johnson & Johnson Reveals Promising Results for JNJ-2113 in FRONTIER 2 Study
Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.
Trends in Cosmeceuticals and Nutraceuticals: Exosomes and Adaptogens Take Center Stage
Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.
Anticipated FDA Approval of Bimekizumab for HS: Insights From Investigator Christopher Sayed, MD
The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.